bl-4162a and Adenocarcinoma-of-Lung

bl-4162a has been researched along with Adenocarcinoma-of-Lung* in 1 studies

Other Studies

1 other study(ies) available for bl-4162a and Adenocarcinoma-of-Lung

Article	Year
Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8 Thrombocytosis is a common paraneoplastic syndrome in patients with lung cancer. However, complications associated with malignancy-related thrombocytosis, including thrombosis and hemorrhage, have rarely been reported. In this case, we describe a 57-year-old man with unresectable adenocarcinoma of the lung who presented with a platelet count over 100 × 10(4)/mm(3). In addition, deep venous thrombosis of the left femoral vein was found during admission. The circumference of the left lower leg and platelet count progressed during the period without chemotherapy and anticoagulants; however, with the addition of anagrelide they improved. We provided an adjuvant therapy with platelet-lowering therapy to treat cancer-induced thrombocytosis during the period without chemotherapy. Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Femoral Vein; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis	2012

Article

Year

Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.

Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8

Thrombocytosis is a common paraneoplastic syndrome in patients with lung cancer. However, complications associated with malignancy-related thrombocytosis, including thrombosis and hemorrhage, have rarely been reported. In this case, we describe a 57-year-old man with unresectable adenocarcinoma of the lung who presented with a platelet count over 100 × 10(4)/mm(3). In addition, deep venous thrombosis of the left femoral vein was found during admission. The circumference of the left lower leg and platelet count progressed during the period without chemotherapy and anticoagulants; however, with the addition of anagrelide they improved. We provided an adjuvant therapy with platelet-lowering therapy to treat cancer-induced thrombocytosis during the period without chemotherapy.

Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Femoral Vein; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis

2012